Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2018

24.02.2018 | Original Article

Hybrid MR-PET of brain tumours using amino acid PET and chemical exchange saturation transfer MRI

verfasst von: N. A. da Silva, P. Lohmann, J. Fairney, A. W. Magill, A.-M. Oros Peusquens, C.-H. Choi, R. Stirnberg, G. Stoffels, N. Galldiks, X. Golay, K.-J. Langen, N. Jon Shah

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

PET using radiolabelled amino acids has become a promising tool in the diagnostics of gliomas and brain metastasis. Current research is focused on the evaluation of amide proton transfer (APT) chemical exchange saturation transfer (CEST) MR imaging for brain tumour imaging. In this hybrid MR-PET study, brain tumours were compared using 3D data derived from APT-CEST MRI and amino acid PET using O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET).

Methods

Eight patients with gliomas were investigated simultaneously with 18F-FET PET and APT-CEST MRI using a 3-T MR-BrainPET scanner. CEST imaging was based on a steady-state approach using a B1 average power of 1μT. B0 field inhomogeneities were corrected a Prametric images of magnetisation transfer ratio asymmetry (MTRasym) and differences to the extrapolated semi-solid magnetisation transfer reference method, APT# and nuclear Overhauser effect (NOE#), were calculated. Statistical analysis of the tumour-to-brain ratio of the CEST data was performed against PET data using the non-parametric Wilcoxon test.

Results

A tumour-to-brain ratio derived from APT# and 18F-FET presented no significant differences, and no correlation was found between APT# and 18F-FET PET data. The distance between local hot spot APT# and 18F-FET were different (average 20 ± 13 mm, range 4–45 mm).

Conclusion

For the first time, CEST images were compared with 18F-FET in a simultaneous MR-PET measurement. Imaging findings derived from18F-FET PET and APT CEST MRI seem to provide different biological information. The validation of these imaging findings by histological confirmation is necessary, ideally using stereotactic biopsy.
Literatur
1.
Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.CrossRefPubMed
2.
3.
McConathy J, Yu W, Jarkas N, et al. Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. Med Res Rev. 2012;32(4):868–905.CrossRefPubMed
4.
Kratochwil C, Combs SE, Leotta K, et al. Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro-Oncology. 2014;16(3):434–40.CrossRefPubMed
5.
Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012;53(2):207–14.CrossRefPubMed
6.
Heinzel A, Müller D, Langen K-J, et al. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. J Nucl Med. 2013;54(8):1217–22.CrossRefPubMed
7.
Galldiks N, Rapp M, Stoffels G, et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging. 2013;40(1):22–33.CrossRefPubMed
8.
Galldiks N, Stoffels G, Ruge MI, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013;54(12):2046–54.CrossRefPubMed
9.
Ceccon G, Lohmann P, Stoffels G, et al. Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro-Oncology. 2017;19(2):281–8.PubMed
10.
Wolff SD, Balaban RS. NMR imaging of labile proton exchange. J Magn Reson. 1990;86(1):164–9.
11.
Ward KM, Aletrasa H, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson. 2000;143(1):79–87.CrossRefPubMed
12.
Ward K, Balaban R. Determination of pH using water protons and chemical exchange dependent saturation transfer (CEST). Magn Reson Med. 2000;802:799–802.CrossRef
13.
Van Zijl P, Jones C, Ren J, et al. MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc Natl Acad Sci U S A. 2007;104(11):4359–64.CrossRefPubMedPubMedCentral
14.
15.
16.
Zhou J, Payen J, Wilson DA, et al. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med. 2003;9:1085–90.CrossRefPubMed
17.
Jones CK, Schlosser MJ, van Zijl PCM, et al. Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med. 2006;56(3):585–92.CrossRefPubMed
18.
Zhou J, Lal B, Wilson D, et al. Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med. 2003;50(6):1120–6.CrossRefPubMed
19.
Tietze A, Blicher J, Mikkelsen IK, et al. Assessment of ischemic penumbra in patients with hyperacute stroke using amide proton transfer (APT) chemical exchange saturation transfer (CEST) MRI. NMR Biomed. 2014;27(2):163–74.CrossRefPubMed
20.
Heo H-Y, Jones CK, Hua J, et al. Whole-brain amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging in glioma patients using low-power steady-state pulsed chemical exchange saturation transfer (CEST) imaging at 7T. J Magn Reson Imaging. 2016;44(1):41–50.CrossRefPubMed
21.
Sakata A, Okada T, Yamamoto A, et al. Grading glial tumors with amide proton transfer MR imaging: different analytical approaches. J Neuro-Oncol. 2015;122(2):339–48.CrossRef
22.
Zhou J, Tryggestad E, Wen Z, et al. Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med. 2011;17(1):130–4.CrossRefPubMed
23.
Togao O, Yoshiura T, Keupp J, et al. Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro-Oncology. 2014;16(3):441–8.CrossRefPubMed
24.
Zaiss M, Windschuh J, Goerke S, et al. Downfield-NOE-suppressed amide-CEST-MRI at 7 Tesla provides a unique contrast in human glioblastoma. Magn Reson Med. 2017;77(1):196–208.CrossRefPubMed
25.
Jones CK, Huang A, Xu J, et al. Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T. NeuroImage. 2013;77:114–24.CrossRefPubMed
26.
Paech D, Zaiss M, Meissner J-E, et al. Nuclear overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 Tesla in glioblastoma patients. PLoS One. 2014;9(8):e104181.CrossRefPubMedPubMedCentral
27.
Schlemmer H, Pichler B, Schmand M. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008;248(3).
28.
Harris RJ, Cloughesy TF, Liau LM, et al. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology. 2015;17(11):1514–24.CrossRefPubMedPubMedCentral
29.
Harris RJ, Cloughesy TF, Liau LM, et al. Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T. NMR Biomed. 2016;29(11):1563–76.CrossRefPubMed
30.
Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128(3):678–87.CrossRefPubMed
31.
Herzog H, Langen K-J, Weirich C, et al. High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin. 2011;50(2):74–82.CrossRefPubMed
32.
Jones C, Polders D, Hua J. In vivo 3D whole-brain pulsed steady state chemical exchange saturation transfer at 7T. Magn Reson Med. 2012;67(6):1579–89.CrossRefPubMed
33.
Stirnberg R, Pflugfelder D, Stöcker T, Shah NJ. High-Resolution 3D-fMRI at 9.4 Tesla with Intrinsically Minimised Geometric Distortions. Proc Intl Soc Mag Reson Med. 2013;2372.
34.
Stirnberg R, Brenner D, Stöcker T, Shah NJ. Rapid fat suppression for three-dimensional echo planar imaging with minimized specific absorption rate. Magn Reson Med. 2016;76(5):1517–23.CrossRefPubMed
35.
36.
Hamacher K, Coenen HH. Efficient routine production of the 18 F-labelled amino acid O-2-18F-fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002;57:853–6.CrossRefPubMed
37.
Langen K-J, Bartenstein P, Boecker H, et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nuklearmedizin. 2011;50(4):167–73.CrossRefPubMed
38.
Kops E, Hautzel H, Herzog H, et al. Comparison of template-based versus CT-based attenuation correction for hybrid MR/PET scanners. IEEE Trans Nucl Sci. 2015;62(5):2115–21.CrossRef
39.
Weirich C, Scheins J, Lohmann P, et al. Quantitative PET imaging with the 3T MR-BrainPET. Nucl Instruments Methods Phys Res Sect A Accel Spectrometers Detect Assoc Equip. 2013;702:26–8.CrossRef
40.
Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143–56.CrossRefPubMed
41.
Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage. 2002;17(2):825–41.CrossRefPubMed
42.
Zhang Y, Heo H-Y, Lee D-H, et al. Selecting the reference image for registration of CEST series. J Magn Reson Imaging. 2016;43(3):756–61.CrossRefPubMed
43.
Abdul-Rahman HS, Gdeisat M, Burton DR, et al. Fast and robust three-dimensional best path phase unwrapping algorithm. Appl Opt. 2007;46(26):6623.CrossRefPubMed
44.
Henkelman R, Huang X, Xiang QS, et al. Quantitative interpretation of magnetization transfer. Magn Reson Med. 1993;29(6):759–66.CrossRefPubMed
45.
Morrison C, Henkelman RM. A model for magnetization transfer in tissues. Magn Reson Med. 1995;33(4):475–82.CrossRefPubMed
46.
Heo H-Y, Zhang Y, Jiang S, et al. Quantitative assessment of amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging with extrapolated semisolid magnetization transfer reference (EMR) signals: application to a rat glioma model at 4.7 Tesla. Magn Reson Med. 2016;75(1):137–49.CrossRefPubMed
47.
Heo H-Y, Zhang Y, Jiang S, et al. Quantitative assessment of amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging with extrapolated semisolid magnetization transfer reference (EMR) signals: II. Comparison of three EMR models and application to human brain glioma at 3T. Magn Reson Med. 2016;75(4):1630–9.CrossRefPubMed
48.
Heo H-Y, Lee D-H, Zhang Y, et al. Insight into the quantitative metrics of chemical exchange saturation transfer (CEST) imaging. Magn Reson Med. 2017;77(5):1853–65.CrossRefPubMed
49.
Lohmann P, Herzog H, Rota Kops E, et al. Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. Eur Radiol. 2015;25(10):3017–24.CrossRefPubMed
50.
Sakata A, Fushimi Y, Okada T, et al. Diagnostic performance between contrast enhancement, proton MR spectroscopy, and amide proton transfer imaging in patients with brain tumors. J Magn Reson Imaging. 2017;46(3):732–9.CrossRefPubMed
51.
Albert NL, Winkelmann I, Suchorska B, et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans. Eur J Nucl Med Mol Imaging. 2016;43(6):1105–14.CrossRefPubMed
52.
Langen K-J, Hamacher K, Weckesser M, et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33(3):287–94.CrossRefPubMed
53.
Yan K, Fu Z, Yang C, et al. Assessing amide proton transfer (APT) MRI contrast origins in 9 L Gliosarcoma in the rat brain using proteomic analysis. Mol Imaging Biol. 2015;17(4):479–87.CrossRefPubMedPubMedCentral
54.
Sun PZ, Sorensen G. Imaging pH using the chemical exchange saturation transfer (CEST) MRI: correction of concomitant RF irradiation effects to quantify CEST MRI for chemical exchange rate and pH. Magn Reson Med. 2008;60(2):390–7.CrossRefPubMed
55.
Zhao X, Wen Z, Huang F, et al. Saturation power dependence of amide proton transfer image contrasts in human brain tumors and strokes at 3 T. Magn Reson Med. 2011;66(4):1033–41.CrossRefPubMedPubMedCentral
56.
Desmond KL, Stanisz GJ. Understanding quantitative pulsed CEST in the presence of MT. Magn Reson Med. 2012;67(4):979–90.CrossRefPubMed
57.
Zaiss M, Kunz P, Goerke S, et al. MR imaging of protein folding in vitro employing nuclear-Overhauser-mediated saturation transfer. NMR Biomed. 2013;26(12):1815–22.CrossRefPubMed
58.
Griffiths J. Are cancer cells acidic? Br J Cancer. 1991;427(3):425-427.
59.
Ross B, Higgins RJ, Boggan JE, et al. 31P NMR spectroscopy of the in vivo metabolism of an intracerebral glioma in the rat. Magn Reson Med. 1988;6(4):403–17.CrossRefPubMed
60.
Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med. 1997;38(9):1459–62.PubMed
61.
62.
Kracht LW, Miletic H, Busch S, et al. Delineation of brain tumor extent with [ 11 C ] L -Methionine positron emission Tomography : local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10:7163–70.CrossRefPubMed
63.
Stegmayr C, Bandelow U, Oliveira D, et al. Influence of blood-brain barrier permeability on O-(2-(18)F-fluoroethyl)-L-tyrosine uptake in rat gliomas. Eur J Nucl Med Mol Imaging. 2017;44(3):408–16.CrossRefPubMed
64.
Schmitt B, Zaiss M, Zhou J, Bachert P. Optimization of pulse train presaturation for CEST imaging in clinical scanners. Magn Reson Med. 2011;65(6):1620–9.CrossRefPubMed
65.
Dula AN, Asche EM, Landman BA, et al. Development of chemical exchange saturation transfer (CEST) at 7T. Magn Reson Med. 2012;66(3):831–8.CrossRef
66.
67.
Shah NJ. Multimodal neuroimaging in humans at 9.4 T: a technological breakthrough towards an advanced metabolic imaging scanner. Brain Struct Funct. 2015;220(4):1867–84.CrossRefPubMed
Metadaten
Titel
Hybrid MR-PET of brain tumours using amino acid PET and chemical exchange saturation transfer MRI
verfasst von
N. A. da Silva
P. Lohmann
J. Fairney
A. W. Magill
A.-M. Oros Peusquens
C.-H. Choi
R. Stirnberg
G. Stoffels
N. Galldiks
X. Golay
K.-J. Langen
N. Jon Shah
Publikationsdatum
24.02.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-018-3940-4

Weitere Artikel der Ausgabe 6/2018

European Journal of Nuclear Medicine and Molecular Imaging 6/2018 Zur Ausgabe

Original Article

Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson’s disease based on [123I]FP-CIT SPECT images

Image of the Month

Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion

Original Article

Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index

Original Article

Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis

Original Article

PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer

Review Article

FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance